ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIRO..CY..TRBGCZEEHUPLSK....IS..............................*JJDIM360 Ver 1.28 (29 Oct 2014) - 2999001/0The file contains technical information submitted after the application was filed and not included in this specification1835929CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120160727W173deBibliographieenBibliographyfrBibliographieEP06700713.8200601062007080620071228enenen20050002620050106DK2016072720163020070926200739201605042016182015111320160727201630A61K 38/20 20060101AFI20150424BHEP A61K 39/00 20060101ALI20150424BHEP A61K 39/395 20060101ALI20150424BHEP A61P 35/00 20060101ALI20150424BHEP C07K 16/28 20060101ALI20150424BHEP deBEHANDLUNGEN UND VERFAHREN MIT ANTI-KIR-KOMBINATIONenANTI-KIR COMBINATION TREATMENTS AND METHODSfrPROCÉDÉS ET TRAITEMENTS COMBINÉS ANTI-KIRWO-A1-2005/009465WO-A2-2005/003172KOH CRYSTAL Y ET AL: "Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo" BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 97, no. 10, 15 May 2001 (2001-05-15), pages 3132-3137, XP002308582 ISSN: 0006-4971 cited in the applicationKOH C Y ET AL: "NK inhibitory-receptor blockade for purging of leukemia: effects on hematopoietic reconstitution" BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, KLUGE CARDEN JENNINGS PUBLISHING, CHARLOTTESVILLE, VA, US, vol. 8, no. 1, 2002, pages 17-25, XP002308879 ISSN: 1083-8791KOGURE T ET AL: "Killer-cell inhibitory receptors, CD158a/b, are upregulated by interleukin-2, but not interferon-gamma or interleukin-4." MEDIATORS OF INFLAMMATION. 1999, vol. 8, no. 6, 1999, pages 313-318, XP008066290 ISSN: 0962-9351SONDEL P M ET AL: "COMBINATION THERAPY WITH INTERLEUKIN-2 AND ANTITUMOR MONOCLONAL ANTIBODIES" CANCER JOURNAL FROM SCIENTIFIC AMERICAN, SCIENTIFIC AMERICAN, INC., NEW YORK, NY, US, vol. 3, no. SUPPL 1, 1997, pages S121-S127, XP009040777 ISSN: 1081-4442FARAG SHERIF S ET AL: "New directions in natural killer cell-based immunotherapy of human cancer." EXPERT OPINION ON BIOLOGICAL THERAPY. APR 2003, vol. 3, no. 2, April 2003 (2003-04), pages 237-250, XP009040774 ISSN: 1471-2598MORETTA A ET AL.: "P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities", J.EXP.MED., vol. 178, August 1993 (1993-08), pages 597-604, XP009005922,CAMBIAGGI A. ET AL.: "Natural killer cell acceptance of H-2 mismatch bone marrow grafts in transgenic mice expressing HLA-Cw3 specific killer cell inhibitory receptor.", PROC. NATL. ACAD. SCI. USA, vol. 94, July 1997 (1997-07), pages 8088-8092, XP002007252,RUGGERI L ET AL.: "Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants", SCIENCE, vol. 295, 15 March 2002 (2002-03-15), pages 2097-2100, XP002382437,VIVIER E AND ANFOSSI N: "Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future", NATURE REVIEWS IMMUNOLOGY, vol. 4, March 2004 (2004-03), pages 190-198, XP008066093,ABI-RACHED L AND PARHAM P: "Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues", J.EXP.MED., vol. 201, no. 8, 18 May 2005 (2005-05-18), pages 1319-1332,11181366.324468972011091516167879.220160502ROMAGNÉ , FrancoisBat A3, Les Hauts de FontsainteF-13600 La CiotatFRWAGTMANN, Peter Andreas Nicolai ReumertVallerød Banevej 34DK-2960 Rungsted KystDKGLAMANN, JoakimIbstrupvej 60DK-2820 GentofteDKNOVO NORDISK A/S100754690M/54291-EPNovo Allé2880 BagsvaerdDKInnate Pharma S.A.101432161M/54291-EP117 Avenue de Luminy13009 MarseilleFRReitstötter Kinzebach100061448Patentanwälte Sternwartstrasse 481679 MünchenDEATBEBGCHCYCZDEDKEEESFIFRGBGRHUIEISITLILTLULVMCNLPLPTROSESISKTREP200605007220060106enWO200607262520060713200628